Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib

Peng He · Gang Li

Received: 15 March 2013 / Accepted: 18 May 2013 / Published online: 8 June 2013 © The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract

Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) is approved for cancer treatment. We investigated whether gefitinib treatment can enhance human EGF (hEGF) uptake in vitro, thereby increasing the potential of hEGF as a vehicle for EGFR-targeted therapy.

Methods Western blotting was used to detect the effect of gefitinib on EGFR signaling. Different EGFR-expressing tumor cells (SCC-1, 22B, A549, and HT-29) were pre-treated with gefitinib, and then with 125I-hEGF or 125I-Vectibix (an anti-EGFR monoclonal antibody). Cell-associated activity was then measured. A cross-linking assay detected increased EGFR dimer formation in gefitinib-treated cells.

Results Total EGFR levels were not changed, but EGFR phosphorylation was reduced in cells pretreated with gefitinib. Gefitinib mediated formation of EGFR dimers; binding of 125I-hEGF to cells pretreated with gefitinib significantly increased. In contrast, binding of 125I-Vectibix to tumor cells did not increase. Although total EGFR levels did not increase, binding of hEGF to EGFR + tumors was significantly enhanced after gefitinib treatment, because of increased hEGF binding to gefitinib-induced EGFR dimers.

Conclusion These results suggest that hEGF could enhance EGFR-targeting when used with gefitinib.

Keywords Gefitinib · hEGF · EGFR · Dimer

Introduction

Receptor tyrosine kinases of the epidermal growth factor receptor (EGFR) family are critical in the etiology and progression of solid tumors. EGFR is associated with essential cellular functions, including proliferation, migration, survival, and differentiation [1, 2]; it is over-expressed in many tumors, including head and neck, renal, lung, glioma, breast, colorectal, prostate, ovarian, bladder and pancreas [3], and prompts more aggressive malignant phenotypes and poor prognoses. For such reasons, EGFR is an attractive target for tumor therapies. Gefitinib (ZD1839, IressaTM) is an anilino-quinazoline derivative that acts as an EGFR-specific pharmacological inhibitor; it decreases EGFR kinase activity by binding the adenosine triphosphate (ATP) pocket of the catalytic domain [4]. Although patients with high EGFR expression reportedly have significantly worse survival, gefitinib induces substantial clinical responses in about 10 % of patients with chemotherapy-refractory NSCLC [5–8]. Generally, gefitinib-responsive lung cancers—but not nonresponsive cancers—harbor mutations within the EGFR kinase domain [9, 10]. These heterozygous mutations include small in-frame deletions and missense substitutions clustered within the ATP-binding pocket.

The natural ligand to the EGFR, hEGF, is a peptide with a molecular weight of about 6 kDa. Reportedly, the EGFR-specific TKIs AG-1478 and AG-1517 both compete with ATP in the classical mode of action, and induce formation of inactive, unphosphorylated EGFR dimers, even in the absence of ligand hEGF [11, 12]. The same phenomenon was also observed in cells treated with gefitinib. Gefitinib induces formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers in HER2-overexpressing breast cancer cells [13]. In A431 cells, gefitinib increased the number of...
EGFR dimers 3.0–3.8 times in the absence of hEGF [14]. In hEGF-stimulated SKOV3 cells, EGFR dimers were also increased 1.8–2.2 times by gefitinib, but this effect was cancelled by pertuzumab [14]. As receptor dimers are thought to have high affinity for their ligand, uptake of $^{211}$At-hEGF in U343 cells markedly increased (up to 3.5 times) in cells pretreated with gefitinib [15]. Gefitinib treatment increased EGFR $B_{\text{max}}$ by membrane stabilization of inactive receptor dimers in the absence of hEGF [16].

Taken together, we supposed that gefitinib induces EGFR dimer formation, thus affecting ligand interactions. This indicates that combined gefitinib treatment and radionuclide targeting to EGFR would be a useful therapeutic modality, even for patients who express high EGFR levels and do not respond to treatment with gefitinib alone or other EGFR-targeted therapeutic methods.

**Materials and methods**

**Cell culture**

Four cell lines were used: human head and neck squamous carcinoma cell line UM-SCC-22B and SCC1, human colon carcinoma cell line HT29, and human nonsmall cell lung carcinoma cell line A549. All cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) at 37°C in 5 % CO$_2$.

**Radiolabeling**

Human epidermal growth factor (hEGF, Chemicon International, USA) and Vectibix (an anti-EGFR mAb, Amgen, Inc.) were labeled with $^{125}$I (Beijing Atom High Tech, Beijing, China) using the Iodogen method for all cellular experiments. The methods were performed as described previously [17–19].

**Cell-binding assay**

Different EGFR-expressing tumor cells seeded in 24-well plates were pretreated with gefitinib at a single dose (400 nM) for 1 h at 4°C, incubated by addition of $^{125}$I-hEGF or $^{125}$I-Vectibix for another 2 h at 4°C. The total volume of each well was adjusted to 200 µl. Nonspecific binding at each well was determined by adding the same dose of $^{125}$I-hEGF or $^{125}$I-Vectibix in the absence of cells. After incubation, the reaction medium was removed and cells were washed with ice-cold PBS. Cells were lysed with 2 M NaOH, and cell-associated radioactivity was measured using a gamma counter (Wallac 1470-002, Perkin-Elmer, Finland). Results were analyzed by GraphPad Prism 4.0 (GraphPad Software, San Diego, CA). Data were expressed as the average of triplicate samples. Cells were administered with DMSO as vehicle control.

Cells were pretreated with gefitinib at a continuous dose of 0.01, 0.05, 0.1, 0.5, 1, 5, or 10 µM for 1 h at 4°C, incubated by addition of $^{125}$I-hEGF for another 2 h at 4°C. Then, the next steps were performed as described above.

hEGF affinities that were affected by gefitinib were determined by performing competitive displacement studies using $^{125}$I-hEGF as the radioligand. $^{125}$I-hEGF was prepared by labeling hEGF with Na$^{125}$I at a high specific activity (RCP $= 100\%$) according to the method described previously. Briefly, multiscreen DV filter plates were seeded with $\sim 10^5$ cells in the binding buffer and incubated with gefitinib at a single dose (10 nM) for 1 h at 4°C. Cells were then washed with ice-cold PBS and incubated with $^{125}$I-hEGF in the presence of increasing concentrations of hEGF (0–10 µg/ml). After removing the unbound $^{125}$I-hEGF, hydrophilic PVDF filters were collected and the radioactivity was determined using a gamma counter (Packard, Meriden, CT). All the in vitro experiments were carried out twice with triplicate samples. Nonspecific binding at each well was determined by adding a high concentration of cold hEGF (400 ng/ml) that completely displaced ($>95\%$) radiolabeled hEGF binding. Cells treated with DMSO were used as control. Results were calculated by nonlinear regression using GraphPad Prism (GraphPad Software, Inc., San Diego, CA), and reported as an average of these samples plus the standard deviation. For comparison purposes, we also evaluated Vectibix using the same method in vitro assay.

**Western blotting**

Different EGFR-expressing tumor cells were pretreated with gefitinib at different concentrations in the presence of hEGF (10 µM). Cells were then collected and lysed in cell lysis buffer (50 mM Tris–HCl, pH 7.4, 1 % NP-40, 0.25 % sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 1 mM Na$_3$VO$_4$, 1 mM NaF) containing protease inhibitors. After the insoluble part of the lysates was cleared by centrifugation, protein concentrations were determined by the BCA Protein Assay Kit (Pierce). Forty micrograms of proteins was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a nitrocellulose (NC) membrane. The primary antibodies used for western blot analysis were against EGFR (SC-05, Santa Cruz), and pEGFR (#2231, Cell Signaling). GAPDH was used as loading control. Bands were detected by enhanced chemiluminescent western blotting detection system (GE Healthcare). Films were then scanned by grayscale mode, and the images were opened in ImageJ (http://rsb.info.nih.gov/ij/).
Cross-linking assay

Before cross-linking, the cells were serum-starved for 24 h in 0.1 % FBS DMEM. Cells were then exposed to gefitinib at concentrations of 0, 0.01, 0.05, 0.1, 0.5, 1, 5, or 10 μM (final concentration) for 1 h at 37 °C, followed by incubation with 100 ng/ml hEGF, or without hEGF as positive control. After being washed three times with ice-cold PBS, 1 mM of the cross-linking reagent BS3 in cold PBS was added to cells and maintained on ice for 30 min. The reaction was stopped by 500 mM (final concentration) of glycine in PBS for 5 min at 4 °C. Subsequently, cells were washed with ice-cold PBS, and then scraped in lysis buffer as described previously. After centrifugation at 10,000 g for 15 min at 4 °C, the supernatants were collected and protein concentrations were determined by the BCA Protein Assay Kit (Pierce). Proteins were separated by SDS-PAGE on 6 % gel; western blot analysis was done as described previously. The primary antibodies were against EGFR (SC-05, Santa Cruz). An ROI was drawn on the first lane; the same size/shape ROI was also applied to the other lanes. Each intensity band correlated with the cell-binding data.

Statistical analysis

Quantitative data were expressed as mean ± SD. Statistical analysis was done by one-way ANOVA and Student’s t test. P < 0.05 was considered statistically significant (GraphPad Prism 4.0).

Results

Effects of gefitinib on EGFR expression and receptor phosphorylation

To determine the effects of gefitinib on EGFR expression and receptor phosphorylation, four tumor cells (SCC-1, 22B, A549, and HT-29) were pretreated with gefitinib at 0.00, 0.05, 0.1, 0.5, or 1 μM in the presence of hEGF (10 ng/ml), followed by western blot analysis. As shown in Fig. 1a, these four cell lines showed even levels of EGFR expression, which was not affected by gefitinib, but the phosphorylation of EGFR showed dose-dependent decrease when treated with gefitinib. However, phosphorylation of EGFR in 22B cells did not indicate a dose-dependent decrease.

Effects of gefitinib on 125I-hEGF binding to cells

Cells were pretreated with gefitinib at a single dose (400 nM), followed by addition of 125I-hEGF or 125I-Vectibix. Binding of 125I-hEGF to gefitinib-treated cells was significantly increased, whereas binding of 125I-Vectibix to tumor cells did not increase (Fig. 1b).

Gefitinib mediated formation of EGFR dimer complexes

EGFR dimerization is reportedly induced by its specific ligand; it is also mediated by quinazoline derivatives in the absence of growth factor [13]. We verified that this phenomenon appeared in different EGFR-expressing tumor cells (A549, 22B, HT-29, and SCC1) after gefitinib treatment. EGFR dimer formation was detected by western blot experiments, after membrane protein cross-linking, following administration of gefitinib. EGFR monomers (molecular mass 170 kDa) were present in both untreated and drug-treated cells at equal amounts, even at different doses of gefitinib (Fig. 2). However, clear dimerization of EGFR (at ~360 kDa immunoreactive bands) was also evident in the four different tumor cells, and in cells exposed to hEGF (100 ng/ml) treatment; such dimerization gradually increased with the dose of gefitinib at 0.01, 0.05, 0.1, 0.5, 1, 5, and 10 μM (final concentration). Notably, SCC1 cells floated when doses of gefitinib exceeded 0.5 μM, so we only obtained results from 0 to 0.5 μM doses.

hEGF uptake correlated with increased EGFR dimer formation and change of gefitinib dose

To determine the correlation between hEGF uptake increase and EGFR dimer formation, we also carried out cell binding of 125I-hEGF after gefitinib treatment at continuous doses of 0.01, 0.05, 0.1, 0.5, 1, 5, or 10 μM in cells. We then conducted quantitative densitometry of EGFR dimers, compared the results with those of 125I-hEGF cell binding at continuous gefitinib doses, and analyzed the correlation between hEGF uptake increase and EGFR dimer formation. Western blot analysis of EGFR dimers by ImageJ was used to obtain quantitative data (Fig. 3). Relative hEGF uptake was calculated to correlate with the EGFR dimer formation. In all four tumor cell lines, EGFR dimerization and specific binding of hEGF increased with increased gefitinib dose. We therefore supposed that increased hEGF uptake has a better linear correlation of EGFR dimer formation with the change in gefitinib dose, \( r^2 = 0.9127 \) in A549, \( r^2 = 0.9464 \) in 22B, \( r^2 = 0.6426 \) in HT29, and \( r^2 = 0.6417 \) in SCC1; \( P < 0.0001 \).

Gefitinib increased number of hEGF receptor sites

The receptor-binding affinity of hEGF treated with gefitinib was determined using competitive displacement
studies, with Vectibix as control. hEGF and Vectibix inhibited binding of $^{125}\text{I}}$-hEGF and $^{125}\text{I}}$-Vectibix to cells, in a concentration-dependent manner (Fig. 4). The results suggest that the gefitinib did not affect the receptor-binding affinities of hEGF and Vectibix. However, hEGF receptor site numbers increased after gefitinib treatment, whereas those for Vectibix did not change, which indicates that gefitinib caused a dramatic increase in radioligand specific binding.

**Discussion**

Because of the apparent role of EGFR in tumor aggression and poor prognosis, and its high expression in many types of cancers, the EGFR pathway has been well investigated as a possible target in cancer therapies. Increasing clinical evidence has shown the disparity between the EGFR expression level and the treatment effect of anti-EGFR mAb-based immunotherapeutic agents [20–22]. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib represent another strategy for EGFR-targeted cancer therapy. However, gefitinib induces substantial clinical responses in only about 10% of patients with chemotherapy-refractory NSCLC [5–8]. Besides EGFR expression levels, other factors, such as EGFR mutations, tumor microenvironment, tumor vasculature density and permeability, tumor interstitial pressure, pharmacokinetics, and tumor penetration ability of compounds, could influence anti-EGFR treatments [8, 9, 23, 24].

In our study, western blot was performed with different EGFR-expressing tumor cells (SCC-1, 22B, A549, and HT-29) to detect the effects of gefitinib on EGFR expression.

![Fig. 1 a Effects of gefitinib on EGFR expression and receptor phosphorylation in A549, 22B, HT29, and SCC1 cancer cells. b Binding of $^{125}\text{I}}$-hEGF to cancer cells pretreated with 400 nM gefitinib. The values on the y-axis give the percentage of added radioactivity. Each data point is an average value from three wells ± maximum error](image-url)
and receptor phosphorylation. Although the total EGFR levels were unchanged, EGFR phosphorylation was reduced in SCC1, HT29, and A549 cells pretreated with gefitinib (Fig. 1a). However, in 22B cells, EGFR phosphorylation was not decreased in a significant dose-dependent manner when treated with gefitinib, which suggests that the 22B tumor cells are tolerant to gefitinib. When $^{125}$I-hEGF was added to cells pretreated with gefitinib, an unexpected two–threefold increase was observed (Fig. 1b). Furthermore, the increase was dependent on the drug concentration (Fig. 3). However, $^{125}$I-Vectibix did not show the same increase (Fig. 1b). Our results indicate that hEGF uptake was significantly increased after gefitinib treatment in EGFR$^{-}$ cells, even in the cells tolerant to gefitinib.

hEGF can induce transphosphorylation of their receptors, mainly by forming monomeric receptors into active dimers. However, quinazoline drugs can induce sequestration of EGFR into inactive dimers [25], and trap the ligand into those complexes, which can block the ligand from binding to still-functional receptors. This pattern is consistent with gefitinib directly promoting formation of inactive EGFR-based homodimers or heterodimers (EGFR/HER2, EGFR/HER3) in several breast carcinoma cell lines [13]. Gefitinib is reported to competitively inhibit ATP binding at the catalytic site of EGFR tyrosine kinase [26]. Some studies showed that gefitinib can cause complete and long-lasting inhibition of EGFR phosphorylation, which depends on sequestration of inactive drug–receptor complexes in breast and ovarian carcinomas [13, 27]. Interaction of anilino-quinazoline-induced receptor dimerization at the ATP-binding site has been reported even in the absence of ligand binding [11]. Therefore, we hypothesized that the increased hEGF uptake may be due to gefitinib-induced formation of inactive dimers, and such dimers could be responsible for the apparent increase in

![Chemical cross-linking to evaluate EGFR dimerization after gefitinib and/or EGF treatment in A549, 22B, HT29, and SCC1 cancer cells. EGFR dimer formation was evaluated by analysis of gray value](image)
Fig. 3 Correlation of hEGF tumor uptake and formation of EGFR dimer dose dependent on gefitinib in A549, 22B, HT29, and SCC1 cancer cells.

Fig. 4 In vitro inhibition of $^{125}$I-hEGF (left) and $^{125}$I-Vectibix (right) binding to EGFR on A549, 22B, HT29, and SCC1 cancer cells by hEGF (left) and Vectibix (right). Points mean ($n = 3$), bars SD.
EGFR binding sites. We confirmed significantly increased EGFR dimerization after gefitinib treatment, which gradually increased with gefitinib dose (Fig. 2). An even better linear correlation between hEGF uptake increase and EGFR dimer formation was seen as gefitinib dose increased (Fig. 3). Additionally, the dimers stabilized in the non-phosphorylated (inactive) state in the presence of hEGF (data not showed), as previously reported [14]. Thus, stabilization of inactive dimers may represent another way by which gefitinib impairs EGFR activity. The competitive cell-binding assay showed that the affinity of EGFR was not significantly changed after gefitinib treatment, but the hEGF receptor site numbers (but not those for Vectibix) were increased after gefitinib treatment (Fig. 4). It may be hypothesized that either the gefitinib-dependent EGFR dimerization exposed new binding sites in the inactivated receptors or that dimerization allows hEGF access to spare receptors sequestered in membrane compartments that prevent ligand binding in untreated cells.

Although our previous study [25] independently demonstrates that formation of nonfunctional EGFR dimers can be induced by gefitinib, the exact molecular mechanism linking both events is unclear. However, this study is the first to report the correlation between increased $^{125}$I-hEGF and EGFR dimer formation with changes in gefitinib dose.

In summary, the main goal of this study was to establish a basis for investigating the mechanism of gefitinib-mediated increase in hEGF uptake. Although total EGFR levels did not increase, the binding of hEGF to EGFR + tumors was significantly enhanced after gefitinib treatment, which is likely due to hEGF binding to increased numbers of gefitinib-induced EGFR dimers. These results suggest that hEGF could enhance EGFR-targeting when used with gefitinib.

Acknowledgments We thank Prof. Wang Fan for providing the radioactive platform. The authors express their gratitude to the National Natural Science Foundation of China (No. 81072710), Beijing Natural Science Foundation (No. 7101006), Guangdong Natural Science Foundation (No. 201200101732), and the Research Grant of Shenzhen Basic Research Project (JCYJ20120616153140835) for financial support.

Conflict of interest The authors have no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW (2003) Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284:31–53
2. Earp HS, Dawson TL, Li X, Yu H (1995) Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35:115–132
3. Herbst RS, Shin DM (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer. Cancer 94:1593–1611
4. Wakeling AE, Guy SP, Woodburn JR (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749–5754
5. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292–4302
6. Fukuoka M, Yano S, Giaccone G, Tamura N, Nakagawa K, Douillard J-Y (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246
7. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III Trial-INTACT 1. J Clin Oncol 22:777–784
8. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Assoc 290:2149–2158
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139
10. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500
11. Arteaga CL, Ramsey TT, Shader LW, Geyer CA (1997) Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem 272:23247–23254
12. Han GK, Walker F, Burgess AW, Rigopoulos A, Scott AM, Johns TG (2007) The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. J Biol Chem 282:2840–2850
13. Amido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J (2003) ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9:1274–1283
14. Bjorkelund H, Gedda L, Barta P, Malmqvist M, Andersson K (2003) Epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Cancer Res 63:209:2149–2158
15. Sundberg AL, Almqvist Y, Tolmachev V, Carlsson J (2003) Treatment of cultured glioma cells with the EGFR-TKI gefitinib (“Iressa”, ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition. Eur J Nucl Med Mol Imag 30:727–729
16. Favoni RE, Patarozzi A, Lo Castro M, Barbieri F, Gatti M, Pal-eari L (2010) Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation. Curr Cancer Drug Target 10:176–191
17. Shao W, Zhao S, Liu Z, Zhang J, Ma S, Sato JD (2006) Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibodies mitomycin C. Biochem Biophys Res Commun 349:816–824
18. Liu Z, Yu Z, He W, Ma S, Sun L, Wang F (2009) In-vitro internalization and in vivo tumor uptake of anti-EGFR monoclonal antibody LA22 in A549 lung cancer cells and animal model. Cancer Biother Radio 24:15–24

19. Hunter WM, Greenwood FC (1962) Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature 194:495–496

20. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208

21. Hebbar M, Wacrenier A, Desauw C (2006) Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 17:855–857

22. Lenz HJ, Van Cutsem E, Khambata-Ford S (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24:4914–4921

23. Niu G, Li Z, Xie J, Le QT, Chen X (2009) PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 50:1116–1123

24. Aerts HJ, Dubois L, Perk L (2009) Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 50:123–131

25. Lichtner RB, Menrad A, Sommer A, Klar U, Schneider MR (2001) Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 61:5790–5795

26. Ward WH, Cook PN, Slater AM, Davies DH, Holdgate GA, Green LR (1994) Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 48:659–666

27. Sewell JM, Macleod KG, Ritchie A, Smyth JF, Langdon SP (2002) Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (“Iressa”). Br J Cancer 86:456–462